A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line metastatic urothelial carcinoma

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506385-30-00

Acronym

MK-3475-04B

Enrollment

Registered

2024-02-07

Start date

2023-05-22

Completion date

Unknown

Last updated

2025-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Urothelial Carcinoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Italy, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026